If you have been reading about plasma peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
On 1 May 1999 Pudzianowski entered his first Strongman competition, held in Płock, Poland. He achieved his first major success at the international level at the 2000 World's Strongest Man contest where he finished fourth in his first WSM competition. Due to his prison sentence, he did not return for the 2001 competition. Pudzianowski returned at the 2002 World's Strongest Man and won his first title. He retained his title at the 2003 World's Strongest Man with an event to spare, winning by the largest margin ever achieved in the competition; across the seven disciplines in the final, he scored a remarkable four first place finishes, two second place finishes and one third place finish, resulting in the points margin between first and second (20) being greater than the margin between second and ninth (18). British strongman Laurence Shahlaei has since called this performance the most dominant victory ever seen at a World's Strongest Man event. In March 2004, he also became the Strongman Super Series World Champion. He initially finished third in the 2004 World's Strongest Man but was later disqualified for breaching the governing body's Strongman Health Policy. He was forced to return his prize money, stripped of the International Federation of Strength Athletes points from the event, and received a one-year ban from competition. Pudzianowski did not dispute his banned substance violation and waived his right to have his stool sample verified. In 2005, he made his return to World's Strongest Man event.
Angiomas: These are vascular tumours, including haemangioma, lymphangioma, venus varix. Angiomas are difficult to classify as previously they were considered hamartomas, benign tumour-like malformations but there is debate if they are developmental abnormality, true benign tumour or hamartoma, or can be either. Haemangiomas are common in the oral mucosa but can occur in other structures such as salivary glands, and can be congenital or develop in childhood. Congenital lesions can resolve spontaneously (involute) but those that develop later usually continue to slowly grow. They are usually dark red-purple or blue, soft, sometimes fluctuant and painless. They commonly blanch on pressure. Usually solitary, they can occur as part of syndromes such as Sturge–Weber syndrome affecting the trigeminal nerve. They are at risk of trauma with subsequent excessive bleeding, thrombosis or calcification. Lymphangiomas are far less common in the oral mucosa, usually appearing on the tongue, less commonly the lip at birth or in infancy. They are colourless to pale pink and may be nodular projections or resemble "frog spawn" domes. They can cause macroglossia (enlargement of the tongue). Venous varix, like varicose vein, usually appear in older people on the lower lip as a blue-purple lump.
The carnitine shuttle is a biochemical reaction used to transport long chain fatty acids (LCFAs) from the cytosol into the matrix of the mitochondria so that they may be metabolized. While some fatty acids can, long chain fatty acids cannot pass through the mitochondrial membrane. However, carnitine (specifically its stereoisomer l-carnitine) can. The shuttle utilizes this to its advantage by attaching the LCFAs to carnitine. This new acyl-carnitine can pass through the membrane, after which it is split, with the newly separated carnitine being sent back out to shuttle more LCFAs, and the newly separated LCFAs undergoing beta oxidation to release their energy. The carnitine shuttle is an example of an antiporter system, and is a part of the broader class of metabolic reactions that constitute lipid metabolism. It is a highly conserved system found primarily in animals/some eukaryotes, although bacteria and plants still use carnitine for other things such as being an osmoprotectant, or being and electron acceptor in the electron transport chain. The shuttle system is implicated in many metabolic disorders, in the form of deficiencies of the enzymes in the system.
Sources: en.wikipedia.org
=== Hereditary transthyretin-mediated amyloidosis === Inotersen received FDA approval for the treatment of hereditary transthyretin-mediated amyloidosis in October 2018. The application for inotersen was granted orphan drug designation. It was developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by Alnylam Pharmaceuticals, and also approved for use in the US and EU in 2018 with orphan drug designation. Its mechanism-of-action is the active substance of small interfering RNA (siRNA), which allows it to interfere with and block the production of transthyretin. As such, it was the first FDA-approved siRNA therapeutic.
=== Isolation === Muscimol can be extracted from the flesh of the Amanita muscaria by treatment with boiling water, followed by rapid cooling, and further treatment with a basic resin. This is washed with water, and eluted with acetic acid using column chromatography. The eluate is freeze dried, dissolved in water, and passed down a column of cellulose phosphate. A subsequent elution with ammonium hydroxide and recrystallization from alcohol results in pure muscimol. In instances where pure muscimol is not required, such as recreational or spiritual use, a crude extract is often prepared by simmering dried Amanita muscaria in water for 30 minutes.
== Acceptable levels of consumption == The acceptable daily intake (ADI) value for food additives, including aspartame, is defined as the "amount of a food additive, expressed on a body weight basis, that can be ingested daily over a lifetime without appreciable health risk". The Joint FAO/WHO Expert Committee on Food Additives (JECFA) and the European Commission's Scientific Committee on Food (later becoming EFSA) have determined this value is 40 mg/kg of body weight per day for aspartame, while the FDA has set its ADI for aspartame at 50 mg/kg per day – an amount equated to consuming 75 packets of commercial aspartame sweetener per day to be within a safe upper limit. The primary source for exposure to aspartame in the US is diet soft drinks, though it can be consumed in other products, such as pharmaceutical preparations, fruit drinks, and chewing gum among others in smaller quantities. A 12-US-fluid-ounce (350 ml; 12 imp fl oz) can of diet soda contains 0.18 grams (0.0063 oz) of aspartame, and, for a 75-kilogram (165 lb) adult, it takes approximately 21 cans of diet soda daily to consume the 3.7 grams (0.13 oz) of aspartame that would surpass the FDA's 50 mg/kg of body weight ADI of aspartame from diet soda alone. Studies of aspartame consumption in the US, Europe, Australia and other countries have shown that even high levels of intake are well below the ADI for safe consumption.
Sources: en.wikipedia.org
There was a lingering ambiguity in the general notion of "diabetes", especially as it manifests very differently in diabetes mellitus and in diabetes insipidus. In 1843, William Prout aptly summarized the general notion of diabetes of the time as follows:The term diabetes, implying simply an increased flow of urine, is applicable to any disease in which that symptom is present in a remarkable degree. This general use of the term, however, has caused a great deal of confusion; as a variety of diseases differing altogether in their nature, except in the accidental circumstances of being accompanied by diuresis, or a large flow of urine, have in consequence been confounded with one another. To prevent this confusion in future, I would recommend that the term be restricted to those affections in which the urine is saccharine. Hence I define Diabetes to be a disease in which a saccharine state of the urine is the characteristic symptom.
== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system
Bupropion/trazodone (developmental code names S1P-104 and S1P-205; proposed brand names Lorexys and Orexa) is a combination of the norepinephrine–dopamine reuptake inhibitor (NDRI) bupropion and the serotonin antagonist and reuptake inhibitor (SARI) trazodone which is under development for the treatment of erectile dysfunction, female sexual dysfunction, and male sexual dysfunction. It is taken orally. Both bupropion and trazodone have individually been found to be effective and used for treating sexual dysfunction, such as low sexual desire or erectile dysfunction. Bupropion/trazodone is under development by S1 Pharmaceuticals or S1 Biopharma. As of September 2021, it is in phase 2 clinical trials for erectile dysfunction and female sexual dysfunction, whereas no recent development has been reported for male sexual dysfunction.
ACD856, or ACD-856, is a tropomyosin receptor kinase TrkA, TrkB, and TrkC positive allosteric modulator which is under development for the treatment of Alzheimer's disease, depressive disorders, sleep disorders, and traumatic brain injuries. It is taken by mouth.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.